Swipe om te navigeren naar een ander artikel
The aim of this study was to describe the health related quality of life (HRQoL) in different breast cancer disease states using preference-based measures.
A total of 361 consecutive breast cancer patients attending the breast cancer outpatient clinic at Karolinska University hospital Solna for outpatient visits between April and May 2005 were included in the study. The EQ-5D self classifier and a direct Time Trade Off (TTO) question were used to estimate the HRQoL in different breast cancer disease states.
Patients in their first year after a primary breast cancer had a mean EQ-5D index value of 0.696 (95% confidence interval (CI): 0.634–0.747)). Patients in their first year after a recurrence had a mean EQ-5D index value of 0.779 (CI: 0.700–0.849). Patients who had not had a primary breast cancer diagnosis or a recurrence during the previous year had a mean EQ-5D index value of 0.779 (CI: 0.745–0.811). Patients with metastatic disease reported the lowest HRQoL values, and had a mean EQ-5D index value of 0.685 (CI: 0.620–0.735). The main driver behind the reduction in HRQoL was pain and discomfort as well as anxiety and depression. TTO values were higher for all diseases states compared to the EQ-5D index values.
This study shows that breast cancer is associated with a reduction in HRQoL. This effect is most pronounced for patients with metastatic disease.
Log in om toegang te krijgen
Met onderstaand(e) abonnement(en) heeft u direct toegang:
The National Board of Health, Welfare. (2005). Cancer Incidence in Sweden 2004. Stockholm: Official Statistics of Sweden.
The National Board of Health and Welfare. (2005). Causes of death 2003. Stockholm: Official Statistics of Sweden.
Bishop, J. F., Dewar, J., Toner, G. C., et al. (1999). Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer. Journal of Clinical Oncology, 17(8), 2355–2364. PubMed
Chan, S., Friedrichs, K., Noel, D., et al. (1999). Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. Journal of Clinical Oncology, 17(8), 2341–2354. PubMed
Drummond, M., Sculpher, M., Torrance, G., O’Brien, B., & Stoddart G. (2005). Methods for the Economic Evaluation of Health Care Programmes. 3rd ed. Oxford: Oxford Medical Publications.
Torrance, G. (1976). Social preferences for health states: An empirical evaluation of three measurments techniques. Socio-Economic Planning Sciences, 10, 129–136. CrossRef
EuroQol Group. (1990). EuroQol—A new facility for the measurment of health-related quality of life. Health Policy, 16, 199–208. CrossRef
EuroQol Group hompage. http://www.euroqol.org. Accessed November 2nd, 2006.
Gold, M., Siegel, J., Russel, L., & Wienstein, M. (1996). Cost-effectiveness in health and medicine. New York: Oxford University Press.
Johannesson, M. (1996). Theory and Methods of Economic Evaluation of Health. Care: Kluwer Academic Publisher.
Conner-Spady, B. L., Cumming, C., Nabholtz, J. M., Jacobs, P., & Stewart, D. (2005). A longitudinal prospective study of health-related quality of life in breast cancer patients following high-dose chemotherapy with autologous blood stem cell transplantation. Bone Marrow Transplant, 36(3), 251–259. PubMedCrossRef
Hall, J., Gerard, K., Salkeld, G., & Richardson, J. (1992). A cost utility analysis of mammography screening in Australia. Social Science & Medicine, 34(9), 993–1004. CrossRef
Earle, C. C., Chapman, R. H., Baker, C. S., et al. (2000). Systematic overview of cost-utility assessments in oncology. Journal of Clinical Oncology, 18(18), 3302–3317. PubMed
Svenska bröstcancergruppen. (2003). Nationellt vårdprogram för bröstcancer. Stockholm.
Wilson, R. W., Hutson, L. M., & Vanstry, D. (2005). Comparison of 2 quality-of-life questionnaires in women treated for breast cancer: The RAND 36–Item Health Survey and the Functional Living Index-Cancer. Physical Therapy, 85(9), 851–860. PubMed
Wardley, A., Davidson, N., Barrett-Lee, P., et al. (2005). Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: A randomised, crossover study of community vs hospital bisphosphonate administration. British Journal of Cancer, 92(10), 1869–1876. PubMedCrossRef
Peppercorn, J., Herndon, J., 2nd, Kornblith, A. B., et al. (2005). Quality of life among patients with Stage II and III breast carcinoma randomized to receive high-dose chemotherapy with autologous bone marrow support or intermediate-dose chemotherapy: Results from Cancer and Leukemia Group B 9066. Cancer, 104(8), 1580–1589. Oct 15.
- Health related quality of life in different states of breast cancer
- Springer Netherlands